Only osimertinib, the FDA- and EMA-approved third-generation inhibitor, remains the first-line therapy and standard treatment for NSCLC patients carrying EGFR mutations [19,21,22]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.